Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma
Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...
A Look at Patient Outcomes in Overlapping Multiple Myeloma and Chronic Lymphocytic Leukemia
Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both...
Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival
Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...
Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials
Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...
TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes
The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...
Shared-Care Model of Post-Consolidation Care Reduces Travel Burden for AML Patients
In Canada, investigators have been evaluating a shared-care model for acute myeloid leukemia (AML) post-consolidation supportive therapy. The collaborative program permits patients to visit...
Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL
The combination of ibrutinib and bendamustine/rituximab (BR) was well-tolerated and did not significantly affect the safety profile of BR in patients with previously treated...
Microtransplantation: A Better Option for AML Patients Without an HLA-Identical Donor?
The optimal therapy for patients with intermediate-risk acute myeloid leukemia (AML) in first complete remission is uncertain. Microtransplantation, the practice of infusing patients with...
Daratumumab Has Favorable Safety Profile in Relapsed/Refractory Multiple Myeloma Patients
For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, management of infusion-related reactions (IRRs) required temporary slowing or stopping of...
Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients
Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...
Current Issue
July 2018 Bonus Mid-Year Edition
This bonus issue features a look at the most recent changes to Maintenance of Certification programs, highlights from recent hematology/oncology meetings, and more.
